
Please try another search
Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 portfolio, including WP1066, WP1193, and WP1220, which are immune/transcription modulators designed to inhibit phosphorylated signal transducer and activator of transcription for brain tumors and pancreatic and other cancers. In addition, it is developing WP1122 portfolio, such as WP1122, WP1096, and WP1097 designed to exploit the uses of inhibitors of glycolysis comprising 2-deoxy-D-glucose for the treatment of pathogenic viruses and various cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.
Name | Age | Since | Title |
---|---|---|---|
Waldemar Priebe | - | - | Co-Founder, Founding Scientist & Chairman of Scientific Advisory Board |
Robert E. George | 74 | 2016 | Independent Director |
John Michael Climaco | 55 | 2017 | Lead Independent Director |
Michael D. Cannon | 79 | 2016 | Independent Director |
Walter V. Klemp | 64 | 2015 | Co-Founder, Chairman, President & CEO |
Martin S. Tallman | - | 2024 | Member of Annamycin Scientific Advisory Board |
Elizabeth A. Cermak | 66 | 2020 | Independent Director |
Joy Yan | 44 | 2022 | Independent Director |
Jorge Eduardo Cortes | - | 2024 | Member of Scientific Advisory Board |
Michael Andreeff | - | 2024 | Member of Scientific Advisory Board |
Giovanni Martinelli | - | 2024 | Member of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review